Translation and commercialization of regenerative medicines

Organized by Julia Polak, Christopher A. Bravery and Catherine Prescott

Introduction
Translation and commercialization of regenerative medicines
J. Polak, C. A. Bravery & C. Prescott

Articles
Safety paradigm: genetic evaluation of therapeutic grade human embryonic stem cells
E. Stephenson, C. M. Ogilvie, H. Patel, G. Cornwall, L. Jacquet, N. Kadeva, P. Braude & D. Ilic

Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues
H. Abdulrazzak, D. Moschidou, G. Jones & P. V. Guillot

Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale

Engineering extracellular matrix through nanotechnology
C. M. Kelleher & J. P. Vacanti

Human endothelial stem/progenitor cells, angiogenic factors and vascular repair
S. M. Watt, A. Athanassopoulos, A. L. Harris & G. Tsaknakis

Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging
N. G. Kooreman & J. C. Wu

Regenerative medicine: the emergence of an industry
R. M. Nerem

Regenerative medicine. Opportunities and challenges: a brief overview
D. J. Polak

Regenerative nanomedicines: an emerging investment prospective?
C. Prescott

Regulating interface science healthcare products: myths and uncertainties
C. A. Bravery

RSIF_7_S6_cover.qxd  10/14/10  2:16 PM  Page 1